BR0209836A - Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk - Google Patents
Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkkInfo
- Publication number
- BR0209836A BR0209836A BR0209836-9A BR0209836A BR0209836A BR 0209836 A BR0209836 A BR 0209836A BR 0209836 A BR0209836 A BR 0209836A BR 0209836 A BR0209836 A BR 0209836A
- Authority
- BR
- Brazil
- Prior art keywords
- dkk
- modulate
- lrp5
- lrp6
- hbm
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 14
- 238000000034 method Methods 0.000 title abstract 12
- 230000003993 interaction Effects 0.000 title abstract 11
- 210000000988 bone and bone Anatomy 0.000 title abstract 8
- 230000000694 effects Effects 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 230000004156 Wnt signaling pathway Effects 0.000 title 2
- 108091023037 Aptamer Proteins 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 108010079855 Peptide Aptamers Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 abstract 14
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 abstract 14
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 abstract 7
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 abstract 7
- 101000990228 Homo sapiens Hemoglobin subunit mu Proteins 0.000 abstract 6
- 102000013814 Wnt Human genes 0.000 abstract 3
- 108050003627 Wnt Proteins 0.000 abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 abstract 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 abstract 1
- -1 LOW LIPID Chemical class 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/50—Amphibians, e.g. Xenopus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29131101P | 2001-05-17 | 2001-05-17 | |
US35305802P | 2002-02-01 | 2002-02-01 | |
US36129302P | 2002-03-04 | 2002-03-04 | |
PCT/US2002/015982 WO2002092015A2 (en) | 2001-05-17 | 2002-05-17 | Reagents and methods for modulating dkk-mediated interactions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209836A true BR0209836A (pt) | 2004-12-07 |
Family
ID=27404041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209836-9A BR0209836A (pt) | 2001-05-17 | 2002-05-17 | Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1395285A4 (pt) |
JP (2) | JP2005512508A (pt) |
AU (1) | AU2002342734B2 (pt) |
BR (1) | BR0209836A (pt) |
CA (1) | CA2446582A1 (pt) |
IL (1) | IL158750A0 (pt) |
WO (1) | WO2002092015A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60235524D1 (de) | 2002-04-17 | 2010-04-15 | Deutsches Krebsforsch | Verfahren zum Screening einer Substanz zur Modulierung der wnt -Signalkaskade. |
US8124087B2 (en) * | 2002-12-05 | 2012-02-28 | Board Of Trustees Of The University Of Arkansas | Methods of controlling bone loss by inhibiting DKK1 |
ATE500837T1 (de) * | 2002-12-05 | 2011-03-15 | Univ Arkansas | Molekulare determinanten des multiplen myeloms und deren verwendung |
US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
EP1636385A4 (en) * | 2003-06-24 | 2010-06-02 | Mirus Bio Corp | INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS |
US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
WO2005049640A2 (en) | 2003-11-17 | 2005-06-02 | Merck & Co., Inc. | Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof |
WO2005049797A2 (en) | 2003-11-17 | 2005-06-02 | Merck & Co., Inc. | Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof |
US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
WO2006015497A1 (en) * | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
CN101641373B (zh) * | 2007-02-08 | 2015-02-11 | 默沙东公司 | Dkk-1的特异性抗体 |
EA201000718A1 (ru) * | 2007-11-02 | 2011-06-30 | Новартис Аг | Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6) |
AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
WO2010129752A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
WO2010131185A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
EP2536761B1 (en) | 2010-02-19 | 2017-09-20 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
NZ602040A (en) | 2010-03-24 | 2014-12-24 | Genentech Inc | Anti-lrp6 antibodies |
MX2012012927A (es) | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
EA201291180A1 (ru) | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
CN107760686B (zh) * | 2016-08-23 | 2021-04-16 | 上海伯豪医学检验所有限公司 | Dkk-1蛋白的核酸适配体及其应用 |
EP3600418A4 (en) * | 2017-03-24 | 2021-01-13 | Yale University | LOW DENSITY LIPOPROTEIN RECEPTOR-BOUND PROTEIN-5 INHIBITION WHICH SUPPRESSES TUMOR FORMATION |
JP7216024B2 (ja) | 2017-05-31 | 2023-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍細胞におけるWntシグナル伝達と拮抗するポリペプチド |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69837542T2 (de) * | 1997-04-15 | 2008-01-31 | Merck & Co, Inc. | Ldl-rezeptor |
AU3510200A (en) * | 1999-03-05 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
JP2004515209A (ja) * | 2000-04-05 | 2004-05-27 | ゲノム セラピューティックス コーポレーション | 11q13.3の高骨量遺伝子 |
DK1285002T3 (da) * | 2000-05-26 | 2007-10-29 | Oscient Pharmaceuticals Corp | Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet |
HUP0303194A2 (hu) * | 2001-02-16 | 2003-12-29 | Genentech, Inc. | DKK-1 és antagonistái alkalmazásai |
BR0209564A (pt) * | 2001-05-11 | 2004-10-26 | Wyeth Corp | Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea |
-
2002
- 2002-05-17 IL IL15875002A patent/IL158750A0/xx unknown
- 2002-05-17 AU AU2002342734A patent/AU2002342734B2/en not_active Ceased
- 2002-05-17 BR BR0209836-9A patent/BR0209836A/pt not_active IP Right Cessation
- 2002-05-17 JP JP2002588934A patent/JP2005512508A/ja not_active Withdrawn
- 2002-05-17 CA CA002446582A patent/CA2446582A1/en not_active Abandoned
- 2002-05-17 EP EP02744162A patent/EP1395285A4/en not_active Withdrawn
- 2002-05-17 WO PCT/US2002/015982 patent/WO2002092015A2/en active IP Right Grant
-
2008
- 2008-11-27 JP JP2008302849A patent/JP2009142274A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2009142274A (ja) | 2009-07-02 |
EP1395285A2 (en) | 2004-03-10 |
IL158750A0 (en) | 2004-05-12 |
CA2446582A1 (en) | 2002-11-21 |
WO2002092015A2 (en) | 2002-11-21 |
AU2002342734B2 (en) | 2007-07-26 |
JP2005512508A (ja) | 2005-05-12 |
EP1395285A4 (en) | 2005-06-01 |
WO2002092015A3 (en) | 2003-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209836A (pt) | Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk | |
Melrose et al. | Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues | |
Bhattoa | Laboratory aspects and clinical utility of bone turnover markers | |
Boylan et al. | Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF‐H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF‐H as a potential ALS biomarker | |
Christensen et al. | The primary cilium coordinates signaling pathways in cell cycle control and migration during development and tissue repair | |
Migliorini et al. | Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review | |
Ram et al. | Bonebiomarkers in periodontal disease: a review article | |
Taylor et al. | Biochemical markers of bone turnover for the clinical assessment of bone metabolism | |
Nedergaard et al. | Serological muscle loss biomarkers: an overview of current concepts and future possibilities | |
Leeming et al. | An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice | |
Procopio et al. | Intra-and interskeletal proteome variations in fresh and buried bones | |
Shen et al. | LRP4 in neuromuscular junction and bone development and diseases | |
BR0209563A (pt) | ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente | |
Brown et al. | A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs | |
PT868519E (pt) | Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2 | |
Sun et al. | Distribution of small integrin-binding ligand, N-linked glycoproteins (SIBLING) in the condylar cartilage of rat mandible | |
ES2335022T3 (es) | Procedimientos y kits para medir complejos adamts13/fxi. | |
Risteli et al. | Products of bone collagen metabolism | |
Cadoff et al. | Mechanistic insights into the cellular effects of a novel FN1 variant associated with a spondylometaphyseal dysplasia | |
Grow et al. | Agrin‐independent activation of the agrin signal transduction pathway | |
Manavalan et al. | Brain-site-specific proteome changes induced by neuronal P60TRP expression | |
Afjehi-Sadat et al. | Differential protein levels and post-translational modifications in spinal cord injury of the rat | |
Kavallaris et al. | Cytoskeleton and Human Disease | |
Kulahin et al. | The neural cell adhesion molecule NCAM2/OCAM/RNCAM, a close relative to NCAM | |
Parra-Torres et al. | Proteomic analysis of rat cartilage: the identification of differentially expressed proteins in the early stages of osteoarthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: WYETH (US) , OSCIENT PHARMACEUTICALS CORPORATION ( Free format text: ALTERADO DE: GENOME THERAUPEUTICS CORPORATION |
|
B25G | Requested change of headquarter approved |
Owner name: WYETH (US) , OSCIENT PHARMACEUTICALS CORPORATION ( Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070045970/RJ DE 11/04/2007. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 11A E 12A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |